Virtual health platform offers an additional pathway to care for the more than 45 million people in

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque p

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque p

Arcutis Biotherapeutics NASDAQ: ARQT executives said ZORYVE continues to post strong growth and outl

Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Confere

WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq:

Expert recommendations focused on the diagnosis and management of genital psoriasis across age group

Expert recommendations focused on the diagnosis and management of genital psoriasis across age group

Arcutis today announced that management will present at the Goldman Sachs 47th Annual Global Healthc

Arcutis Biotherapeutics (ARQT) is evolving into a specialized dermatology platform, leveraging ZORYV

WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: A

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and ma

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.09 per share versus the Za

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which missed th

Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earn

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for

Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 month

Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 month

Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety,

Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety,

Quantum Biopharma (NASDAQ: QNTM - Get Free Report) and Arcutis Biotherapeutics (NASDAQ: ARQT - Get F

WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq:

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused o

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and lower

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy an

TD Cowen analyst Tyler Van Buren maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and r

HC Wainwright & Co. analyst Douglas Tsao maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and rai

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.13 per share which beat the

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused o

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and rai

Following the termination, Arcutis plans to assume responsibility for sales and promotion of ZORYVE

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and raise

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE c

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving effic